Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Slideshows|June 1, 2023
MDD Research Update
Author(s)Brian Miller, MD, PhD, MPH
Looking to stay up to date on MDD research? This research collection reviews outcomes on metabolic abnormalities, biomarkers, and more.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk
2
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
3
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5